Document ID: chunk:federal_register_of_legislation:F2021C00104:schedule:1:p32
Version: federal_register_of_legislation:F2021C00104
Segment Type: schedule
Provision Reference: sch 1 (pt 32/43)
Character Range: 96307–99187

be disclosed under any of the following provisions of the Act (assuming it were protected information):
 (a) section 68C (disclosure to reduce threat to life or health);
 (b) section 68D (disclosure of publicly available information);
 (c) section 68E (disclosure to respond to public comments).
 (2) For subclause (1), the CEO may determine:
 (a) the way in which the information is to be published; and
 (b) the times at which the information is to be published.
 (3) This clause applies in addition to any other provision of the Act or the NAD scheme under which the CEO is required or authorised to disclose or publish information.

4.22A  Other publications permitted by the World Anti‑Doping Code
  The CEO may publish information about an athlete, support person or non‑participant if:
 (a) the information is of a kind that may be publicly disclosed in accordance with Article 14.3.1 of the World Anti‑Doping Code; and
 (b) the publication occurs after notice referred to in that Article has been provided.

Division 4.5—Commencing action against an athlete, support person or non‑participant

4.23  Limitations provision for commencing action
 (1) For subsection 13(3) of the Act, an action may be commenced against an athlete, support person or non‑participant in relation to a possible violation of the anti‑doping rules within 10 years after the violation is alleged to have occurred.
 (2) For subclause (1), an action is commenced against an athlete, support person or non‑participant in relation to a possible violation of the anti‑doping rules when the athlete, support person or non‑participant is given a notification referred to in Article 5.1.2.1 or 5.3.2.1 of the International Standard for Results Management in relation to the possible violation.

Division 4.6—Violations List

4.24  Correcting entries in the Violations List
  For paragraph 19A(7)(a) of the Act, the CEO must correct an error in an entry in the Violations List as soon as practicable after becoming aware of it.

Part 5—ASDMAC functions

5.01  Functions of ASDMAC

Granting therapeutic use exemptions
 (1) The ASDMAC may, on application by or on behalf of an athlete, grant the athlete a therapeutic use exemption, in accordance with the World Anti‑Doping Code and the International Standard for Therapeutic Use Exemptions, that authorises the athlete to use a prohibited substance or a prohibited method for therapeutic purposes.
 (1A) A therapeutic use exemption granted under subclause (1):
 (a) must be in writing; and
 (b) may authorise the use of a prohibited substance or a prohibited method, for therapeutic purposes, at a time before the exemption is granted; and
 (c) may authorise the use of the prohibited substance or prohibited method, for therapeutic purposes, subject to specified conditions.
 (1B) The ASDMAC must give the athlete written notice of a refusal to grant the